Mr. Fleury is a Diagnostic and Life science executive with broad operational exposure and significant Mergers & Acquisition experience on over $500M in transactions.

Mr. Fleury has held a number of senior positions at public companies including Director Corporate Finance and Business Development QIAGEN, a German Life Science tools and Molecular Diagnostic Company.  While at QIAGEN, Mr. Fleury led financial valuation, due diligence, market and strategic analysis of acquisition targets concentrated in healthcare, molecular technologies and diagnostics.  Mr. Fleury also served as the primary contact for US Investor Relations for QIAGEN.

Mr. Fleury started his career in the medical technology sector in 2001 at Digene, a US based molecular diagnostics company, which successfully developed and commercialized the first molecular test for the viral cause of cervical cancer, the Digene HPV Test.  At Digene, Mr. Fleury worked in Investor Relations and Corporate Finance.  Mr. Fleury was also an instrumental participant in QIAGEN’s $1.6 billion acquisition of Digene in 2007.

Mr. Fleury holds B.S. degree in Biology (specializing in Molecular Biology) from Duke University, B.S. degree in Economics from Duke University and a M.B.A. from The Wharton School at the University of Pennsylvania.